Portugal Clinical Trials Regulation: A Comprehensive Framework for EU Compliance and Participant Protection
Portugal Aligns with EU Standards
Portugal clinical trials regulation is now firmly established through Lei n.º 9/2026, published on March 6, 2026, which implements the European Parliament and Council Regulation (EU) No 536/2014 on clinical trials of medicinal products for human use. This law amends the Clinical Research Law (Lei n.º 21/2014) and designates INFARMED, I.P. (National Authority for Medicines and Health Products) as the primary authority for technical-scientific evaluation, authorization decisions, and national contact point. The Comissão de Ética para a Investigação Clínica (CEIC) provides binding ethical assessments. Key provisions emphasize streamlined procedures via the EU Clinical Trials Information System (CTIS), robust participant protections, and enforcement mechanisms, fully aligning Portugal with EU standards for efficient, transparent clinical research.
Coordinated Evaluation Pathways
The updated law includes a coordinated evaluation process where clinical trial applications, submitted through the EU portal under Article 80 of the Regulation, undergo validation by INFARMED, I.P., in consultation with CEIC, confirming scope and dossier completeness per Annex I. INFARMED handles technical-scientific aspects of Part I of the assessment report (Articles 6 and 7 of the Regulation), while CEIC evaluates ethical elements, including informed consent and vulnerable populations. INFARMED consolidates these for timely decisions within regulatory deadlines. For substantial modifications, validation and assessment follow Articles 17-23, with INFARMED issuing final authorizations grounded in joint evaluations and CEIC’s binding opinions, supported by articulated procedures between entities to meet EU timelines. This structure under Portugal clinical trials regulation supports efficient multinational and national trials, including provisions for shorter deadlines on mononational trials via ministerial portaria.
Participant Safeguards Expanded
Trial participants should expect enhanced protections, extending Regulation requirements with national specifics on informed consent, particularly for minors and incapacitated adults. For minors aged 16 or older, both legal representative consent and participant assent are mandatory, with ongoing requirements upon reaching age thresholds. Institutionalized minors or incapacitated adults are generally excluded unless non-participation poses harm, certified by the attending physician. Promoters and investigators bear strict joint liability for trial-related damages, presumed within one year post-participation (extendable by CEIC), mandating insurance coverage. Experimental medicines, auxiliaries, and additional diagnostics are provided free, with post-trial continuation until National Health Service (SNS) access is secured. Contracts between promoters and trial centers, including financial terms per Annex I Point P, require pre- or post-authorization formalization and INFARMED/CEIC guidance, ensuring accountability.
Compliance and Incentive Mechanisms
INFARMED fulfills an oversight role, including inspections of trial sites, manufacturing, and promoter facilities, with provisions for EU-coordinated audits and third-country notifications. Administrative offenses carry fines from €500-€750,000 based on severity, targeting unauthorized trials, notification failures, and non-compliance with good clinical practices, insurance, free provision, or labeling in Portuguese/English. Non-commercial trials and investigator-led studies are exempt from fees set by portaria. Article 28 mandates CTIS integration with the National Clinical Studies Registry for transparent data sharing. These measures, including promoter-funded free treatments and SNS center enhancements as non-profit entities, foster a regulated environment that incentivizes investment while mitigating risks under Portugal clinical trials regulation.
Boosting HEOR and Market Access
Harmonizing with EU Regulation 536/2014, will likely reduce administrative burdens via CTIS, and impose clear cost responsibilities on promoters—such as free medicines, insurance, and post-trial access until reimbursement—which could accelerate evidence generation for reimbursement decisions in the SNS. The new framework also supports faster novel therapy pathways. Overall, it positions Portugal as a competitive hub, enhancing data quality while upholding ethical standards critical to reimbursement negotiations.
